A phase i study of the safety and pharmacokinetics of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma

Oncology

Volumn 80, Issue 1-2, 2011, Pages 50-56

  Ganjoo, Kristen N ^a   Cranmer, Lee D ^b   Butrynski, James E ^c   Rushing, Daniel ^d   Adkins, Douglas ^e   Okuno, Scott H ^f   Lorente, Gustavo ^g   Kroll, Stew ^g   Langmuir, Virginia K ^g   Chawla, Sant P ^h  

^a STANFORD UNIVERSITY   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e WASHINGTON UNIVERSITY   (United States)

^f MAYO CLINIC   (United States)

^g Threshold Pharmaceuticals   (United States)

^h Sarcoma Oncology Center   (United States)

Author keywords

Hypoxia activated prodrug; Phase I clinical trial; Soft tissue sarcoma; TH 302

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; DOXORUBICINOL; GRANULOCYTE COLONY STIMULATING FACTOR; PRODRUG; TH 302; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ABSCESS; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANGIOSARCOMA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACKACHE; CELLULITIS; CLINICAL ARTICLE; CONSTIPATION; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FIBROSARCOMA; HUMAN; HYPERPIGMENTATION; HYPOALBUMINEMIA; HYPOXIA; INFECTION; LEIOMYOSARCOMA; LIPOSARCOMA; LYMPHOCYTOPENIA; MACULOPAPULAR RASH; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SARCOMA; SOFT TISSUE SARCOMA; STOMATITIS; SYNOVIAL SARCOMA; THROMBOCYTOPENIA; VAGINITIS;

ABSCESS; ADULT; AGED; AGED, 80 AND OVER; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELLULITIS; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG ERUPTIONS; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LYMPHOPENIA; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOADJUVANT THERAPY; NEUTROPENIA; NITROIMIDAZOLES; PHOSPHORAMIDE MUSTARDS; SARCOMA; STOMATITIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79957544947     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000327739     Document Type: Article

References (22)

1. Brizel D, Rosner G, Harrelson J, et al: Pretreatment oxygenation profiles of human soft tissue sarcomas. Int J Radiat Oncol Biol Phys 1994; 30: 635-642. (Pubitemid 24304475)
2. Rajendran J, Wilson D, Conrad E, et al: [(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression. Eur J Nucl Med Mol Imaging 2003; 30: 695-704. (Pubitemid 36612952)
3. Francis P, Namlos H, Muller C, et al: Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxiainduced transcription profile signifies metastatic potential. BMC Genomics 2007; 8: 73
4. Brizel DM, Scully SP, Harrelson JM, et al: Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 1996; 56: 941-943. (Pubitemid 26065381)
5. Nordsmark M, Alsner J, Keller J, et al: Hypoxia in human soft tissue sarcomas: adverse impact on survival and no association with p53 mutations. Br J Cancer 2001; 84: 1070-1075. (Pubitemid 32448504)
6. Sun JD, Liu Q, Ahluwalia D, Curd J, Matteucci M, Hart CP: Complementary chemotherapies with TH-302, a novel hypoxia activated prodrug: optimization of dosing regimens and schedules for study in phase 1/2 with docetaxel, gemcitabine, pemetrexed, and doxorubicin. Biosymposia: Hypoxia, Ischemia, and Inflammation, Boston, 2008.
7. Therasse P, Arbuck S, Eisenhauer E, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216. (Pubitemid 30099779)
8. Greene R, Collins J, Jenkins J, et al: Plasma pharmacokinetics of adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols. Cancer Res 1983; 43: 3417-3421. (Pubitemid 13061607)
9. Rodvold K, Rushing D, Tewksbury D: Doxorubicin clearance in the obese. J Clin Oncol 1988; 6: 1321-1327.
10. Weiss G, Infante J, Chiorean E, et al: Phase 1 study of the safety, tolerability and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies. Clin Cancer Res 2011, E-pub ahead of print.
11. Bendell JC, Weiss GJ, Infante JR, et al: Final results of a phase I study of TH-302, a hypoxia-activated cytotoxic prodrug (HAP). J Clin Oncol 2009; 27(suppl):2573.
12. Le Cesne A, Judson I, Crowther D, et al: Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: a trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J Clin Oncol 2000; 18: 2676-2684. (Pubitemid 30463549)
13. Lorigan P, Verweij J, Papai Z, et al: Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group study. J Clin Oncol 2007; 25: 3144-3150. (Pubitemid 47218064)
14. Maurel J, Lopez-Pousa A, de las Penas R, et al: Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish Group for Research on Sarcomas. J Clin Oncol 2009; 27: 1893-1898.
15. Nielsen O, Dombernowsky P, Mouridsen H, et al: Epirubicin is not superior to doxorubicin in the treatment of advanced soft tissue sarcomas: the experience of the EORTC Soft Tissue and Bone Sarcoma Group. Sarcoma 2000; 4: 31-35. (Pubitemid 30480279)
16. Santoro A, Tursz T, Mouridsen H, et al: Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1995; 13: 1537-1545.
17. Primeau A, Rendon A, Hedley D, et al: The distribution of the anticancer drug doxorubicin in relation to blood vessels in solid tumors. Clin Cancer Res 2005; 11: 8782-8788. (Pubitemid 43005929)
18. von Pawel J, von Roemeling R, Gatzemeier U, et al: Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: a report of the international CATAPULT I study group. Cisplatin and tirapazamine in subjects with advanced previously untreated non-small-cell lung tumors. J Clin Oncol 2000; 18: 1351-1359. (Pubitemid 30159856)
19. Williamson S, Crowley J, Lara PJ, et al: Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced nonsmall-cell lung cancer: Southwest Oncology Group Trial S0003. J Clin Oncol 2005; 23: 9097-9104.
20. Borad M, Infante J, Mita A, et al: Multi-arm phase IB study of TH-302 in combination with gemcitabine, docetaxel or pemetrexed (abstract). Eur J Cancer 2009; 7: 128.
21. Giaccia AJ, Simon MC, Johnson R: The biology of hypoxia: the role of oxygen sensing in development, normal function, and disease. Genes Dev 2004; 18: 2183-2194. (Pubitemid 39209567)
22. Krohn KA, Link JM, Mason RP: Molecular imaging of hypoxia. J Nucl Med 2008; 49(suppl 2):129S-148S. (Pubitemid 351948041)